Myasthenia gravis is a chronic autoimmune neuromuscular disorder whose prevalence in adults 65 and older has risen nearly 50% over the past decade. Almost half of all new diagnoses now occur in that age group, and late-onset presentations tend to be more severe. The condition is frequently missed: women see an average of nearly five providers before receiving a diagnosis, with delays measured in months rather than weeks. That delay matters because myasthenic crisis — acute respiratory failure requiring ventilation — occurs in 15 to 20% of patients, and the risk is higher in elderly populations.
AAVBC's Myasthenia Gravis Quick Reference Guide gives primary care clinicians a structured reference for recognizing and managing MG across its full clinical spectrum. It covers antibody classification, MGFA severity staging, crisis recognition, ICD-10 coding distinctions between stable and exacerbation states, thymoma screening, treatment escalation, and MEAT documentation standards — grounded in current MGFA and EAN guideline evidence.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of myasthenia gravis — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder whose prevalence in adults 65 and older has risen nearly 50% over the past decade. Almost half of all new diagnoses now occur in that age group, and late-onset presentations tend to be more severe. The condition is frequently missed: women see an average of nearly five providers before receiving a diagnosis, with delays measured in months rather than weeks. That delay matters because myasthenic crisis — acute respiratory failure requiring ventilation — occurs in 15 to 20% of patients, and the risk is higher in elderly populations.
AAVBC's Myasthenia Gravis Quick Reference Guide gives primary care clinicians a structured reference for recognizing and managing MG across its full clinical spectrum. It covers antibody classification, MGFA severity staging, crisis recognition, ICD-10 coding distinctions between stable and exacerbation states, thymoma screening, treatment escalation, and MEAT documentation standards — grounded in current MGFA and EAN guideline evidence.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of myasthenia gravis — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
